Literature DB >> 15761703

Contribution to variability in response to opioids.

Geoffrey W Hanks1, Colette Reid.   

Abstract

Opioids are the oldest and most effective agents for the short- and long-term control of severe pain, particularly chronic cancer pain palliation. However, morphine and other opioids display wide variations in pharmacological efficacy and tolerability, and a significant number of patients are unable to achieve adequately controlled pain at doses that do not produce intolerable adverse effects. This article reviews factors that affect the efficacy and tolerability of opioid analgesics and clinical strategies for successful pain mangement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15761703     DOI: 10.1007/s00520-004-0730-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  46 in total

1.  Opioids, confusion and opioid rotation.

Authors:  P Hawley; K Forbes; G W Hanks
Journal:  Palliat Med       Date:  1998-01       Impact factor: 4.762

Review 2.  Clinical pharmacokinetics of morphine.

Authors:  P A Glare; T D Walsh
Journal:  Ther Drug Monit       Date:  1991-01       Impact factor: 3.681

3.  Pain, the physiological antagonist of opioid analgesics.

Authors:  G W Hanks; R G Twycross
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

Review 4.  Neurophysiology of opioid poorly responsive pain.

Authors:  A H Dickenson
Journal:  Cancer Surv       Date:  1994

Review 5.  Genetic basis of drug metabolism.

Authors:  Margaret K Ma; Michael H Woo; Howard L McLeod
Journal:  Am J Health Syst Pharm       Date:  2002-11-01       Impact factor: 2.637

6.  The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

Authors:  Jörn Lötsch; Carsten Skarke; Sabine Grösch; Jutta Darimont; Helmut Schmidt; Gerd Geisslinger
Journal:  Pharmacogenetics       Date:  2002-01

Review 7.  The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation.

Authors:  A R Jadad; G P Browman
Journal:  JAMA       Date:  1995-12-20       Impact factor: 56.272

8.  Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites.

Authors:  S E Bartlett; P R Dodd; M T Smith
Journal:  Pharmacol Toxicol       Date:  1994-08

9.  Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure.

Authors:  Russell K Portenoy; Kathleen M Foley; James Stulman; Elizabeth Khan; Jean Adelhardt; Mary Layman; Daniel F Cerbone; Charles E Inturrisi
Journal:  Pain       Date:  1991-10       Impact factor: 6.961

10.  Delirium in terminally ill cancer patients.

Authors:  M J Massie; J Holland; E Glass
Journal:  Am J Psychiatry       Date:  1983-08       Impact factor: 18.112

View more
  8 in total

Review 1.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

2.  Bidirectional effects of fentanyl on dendritic spines and AMPA receptors depend upon the internalization of mu opioid receptors.

Authors:  Hang Lin; Paul Higgins; Horace H Loh; Ping-Yee Law; Dezhi Liao
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

Review 3.  Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

Authors:  Pierangelo Geppetti; Silvia Benemei
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

4.  Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.

Authors:  Iman A Elkiweri; Yan Ling Zhang; Uwe Christians; Ka-Yun Ng; Martha C Tissot van Patot; Thomas K Henthorn
Journal:  Anesth Analg       Date:  2009-01       Impact factor: 5.108

Review 5.  [Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

Authors:  K Güttler; R Sabatowski
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

6.  A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain.

Authors:  Smita Kshirsagar; Robert Gear; Jon Levine; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.745

7.  Distinct effects of individual opioids on the morphology of spines depend upon the internalization of mu opioid receptors.

Authors:  Dezhi Liao; Olga O Grigoriants; Wei Wang; Katie Wiens; Horace H Loh; Ping-Yee Law
Journal:  Mol Cell Neurosci       Date:  2007-05-04       Impact factor: 4.314

Review 8.  Practical management of opioid rotation and equianalgesia.

Authors:  Erwan Treillet; Sophie Laurent; Yacine Hadjiat
Journal:  J Pain Res       Date:  2018-10-29       Impact factor: 3.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.